Pharmacologic treatments for covid-19 patients

Camostat Mesilate vs Placebo


Outpatients

Forest plots
(last update: 2022-03-17)

Hospitalized patients

Forest plots
(last update: 2022-06-10)

Summary of findings
(last update: 2022-07-01)

To access all information :

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=374

Back to your research

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
NCT04657497 jRCT2031200198
CANDLE
Kinoshita T, medRxiv, 2022
Full text
Commentary
Commentary
Private

Camostat Mesilate

Placebo

RCT Patients with suspected or confirmed COVID-19 (asymptomatic-mild) admitted to 21 centers in Japan N=155
Some concerns
Details

Full description

NCT04353284
Chupp G, medRxiv, 2022
Full text
Commentary
Commentary
Mixed

Camostat Mesilate

Placebo

RCT Outpatients with confirmed COVID-19 (mild) treated at a single center in USA. N=70
Some concerns
Details

Full description

NCT04321096 ; EudraCT Number: 2020001,20042
Gunst J, EClinicalMedicine, 2021
Full text
Commentary
Private

Camostat Mesilate

Placebo

RCT Patients with confirmed COVID-19 (mild-severe) admitted to 9 centers in Denmark and Sweden. N=208
Some concerns
Details

Full description